An Overview of Recent Advances and Clinical Applications of Exon Skipping and Splice Modulation for Muscular Dystrophy and Various Genetic Diseases
Authors:
- 1 September 2018
- book chapter
- Published by Springer Nature
- Vol. 1828, 31-55
Abstract
Exon skipping is a therapeutic approach that is feasible for various genetic diseases and has been studied and developed for over two decades. This approach uses antisense oligonucleotides (AON) to modify the splicing of pre-mRNA to correct the mutation responsible for a disease, or to suppress a particular gene expression, as in allergic diseases. Antisense-mediated exon skipping is most extensively studied in Duchenne muscular dystrophy (DMD) and has developed from in vitro proof-of-concept studies to clinical trials targeting various single exons such as exon 45 (casimersen), exon 53 (NS-065/NCNP-01, golodirsen), and exon 51 (eteplirsen). Eteplirsen (brand name Exondys 51), is the first approved antisense therapy for DMD in the USA, and provides a treatment option for ~14% of all DMD patients, who are amenable to exon 51 skipping. Eteplirsen is granted accelerated approval and marketing authorization by the US Food and Drug Administration (FDA), on the condition that additional postapproval trials show clinical benefit. Permanent exon skipping achieved at the DNA level using clustered regularly interspaced short palindromic repeats (CRISPR) technology holds promise in current preclinical trials for DMD. In hopes of achieving clinical success parallel to DMD, exon skipping and splice modulation are also being studied in other muscular dystrophies, such as Fukuyama congenital muscular dystrophy (FCMD), dysferlinopathy including limb-girdle muscular dystrophy type 2B (LGMD2B), Miyoshi myopathy (MM), and distal anterior compartment myopathy (DMAT), myotonic dystrophy, and merosin-deficient congenital muscular dystrophy type 1A (MDC1A). This chapter also summarizes the development of antisense-mediated exon skipping therapy in diseases such as Usher syndrome, dystrophic epidermolysis bullosa, fibrodysplasia ossificans progressiva (FOP), and allergic diseases. Key words Duchenne/Becker muscular dystrophy (DMD/BMD) CRISPR Cas9/Cpf1 genome editing Eteplirsen (Exondys 51) Nusinersen (Spinraza) Usher syndrome Myotonic dystrophy Fibrodysplasia ossificans progressiva (FOP) Laminin-alpha 2 Exon skipping Dystrophic epidermolysis bullosa (DEB)Keywords
This publication has 137 references indexed in Scilit:
- Overactive bone morphogenetic protein signaling in heterotopic ossification and Duchenne muscular dystrophyCellular and Molecular Life Sciences, 2012
- Usher syndrome type 2 caused by activation of an USH2A pseudoexon: Implications for diagnosis and therapyHuman Mutation, 2011
- Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophyNature, 2011
- Conversion of vascular endothelial cells into multipotent stem-like cellsNature Medicine, 2010
- In-frame Dystrophin Following Exon 51-Skipping Improves Muscle Pathology and Function in the Exon 52–Deficient mdx MouseMolecular Therapy, 2010
- Therapeutic exon skipping for dysferlinopathies?European Journal of Human Genetics, 2010
- Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1Human Mutation, 2008
- By‐passing the nonsense mutation in the 4CV mouse model of muscular dystrophy by induced exon skippingThe Journal of Gene Medicine, 2008
- The development of allergic inflammationNature, 2008
- Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatmentEMBO Reports, 2004